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The composition of the intestinal microbiota inﬂuences the development of inﬂammatory
disorders. However, associating inﬂammatory diseases with speciﬁc microbial members of
the microbiota is challenging, because clinically detectable inﬂammation and its treatment
can alter the microbiota’s composition. Immunologic checkpoint blockade with ipilimumab, a
monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)
signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a
prospective study of patients with metastatic melanoma undergoing ipilimumab treatment
and correlate the pre-inﬂammation faecal microbiota and microbiome composition with
subsequent colitis development. We demonstrate that increased representation of bacteria
belonging to the Bacteroidetes phylum is correlated with resistance to the development of
checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved
in polyamine transport and B vitamin biosynthesis is associated with an increased risk of
colitis. Identiﬁcation of these biomarkers may enable interventions to reduce the risk of
inﬂammatory complications following cancer immunotherapy.
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C
omplex microbial communities, known as the microbiota,
colonize the mammalian intestine and contribute to the
host’s health1,2. Healthy individuals harbour distinct
microbial populations in their intestinal tract that vary
markedly in composition3,4. The complexity and plasticity of
the intestinal microbiota represent a signiﬁcant challenge to the
host’s immune defenses, which must balance immune tolerance
of beneﬁcial microbes with inﬂammatory responses against
pathogens. Certain bacterial species are essential for
maintaining a tolerogenic state in the mucosa. Microbial species
from a variety of genera such as Bacteroides, Clostridium and
Faecalibacterium can induce the expansion of T-regulatory cells
or stimulate the production of anti-inﬂammatory cytokines5–7.
Identifying the microbial species that promote homeostasis or
drive inﬂammation has remained a challenge in the clinical
context, in particular with chronic inﬂammatory conditions such
as inﬂammatory bowel disease. Certain bacteria preferentially
expand following inﬂammation, which alters the microbiota’s
composition8–10. Thus, as most patients seek medical attention
after inﬂammation has developed, it is difﬁcult to deﬁne the
microbiota composition that precedes the development of colitis.
Ipilimumab, a monoclonal antibody that blocks the
co-inhibitory molecule cytotoxic T-lymphocyte-associated
antigen-4 (CTLA-4), is an immunomodulatory therapy that
provides effective treatment against metastatic melanoma11.
Inhibition of CTLA-4 signalling dampens negative regulation of
T cells, thereby enhancing anti-tumour responses. Within the ﬁrst
16 weeks of treatment, roughly one-third of recipients develop
intestinal inﬂammation as a result of mucosal immune
dysregulation12–14. The high incidence of colitis in patients
receiving ipilimumab provides an opportunity to characterize the
colonic microbiota before the development of intestinal
inﬂammation. Herein we use next-generation metagenomic
sequencing to identify biomarkers that are associated with
resistance to new-onset, immune-mediated colitis in the context
of immune checkpoint-blockade therapy. Increased faecal
abundance of the Bacteroidetes phylum and three of its families
(Bacteroidaceae, Rikenellaceae and Barnesiellaceae), as well as
microbial genetic pathways involved in polyamine transport and
B vitamin biosynthesis, are correlated with resistance to the
development of colitis following CTLA-4 blockade. This study
provides a novel view of the intestinal microbiota before the
development of colitis and offers insight into preventive
treatments for patients at risk of adverse inﬂammatory events
following immunologic checkpoint blockade.
Results
Colitis development in patients following CTLA-4 blockade.
We analysed the intestinal microbiota of 34 patients enrolled in a
prospective study to correlate pre-colitis faecal composition with
the subsequent development of checkpoint-blockade-induced
colitis. The patients in this study ranged in age between 28 and 85
years, and were diagnosed with metastatic melanoma. In general,
faecal samples were obtained from patients before the ﬁrst dose of
ipilimumab (30/34), although in two patients who subsequently
developed inﬂammation and two patients who remained
inﬂammation free, samples were obtained after initiation of
ipilimumab, but before the onset of colitis. Of the 34 patients, 10
were diagnosed with gastrointestinal inﬂammation between 13
and 57 days after initiation of ipilimumab (Fig. 1a). Patients who
did not develop gastrointestinal inﬂammation following CTLA-4
blockade are herein referred to as colitis free (C-F) and patients
who experienced inﬂammatory complications after CTLA-4
blockade are referred to as having progressed to colitis (PtC).
Patients were assigned a colitis score by retrospective chart
review, which ranged from no diarrhoea (score 0) in C-F patients
to severe colitis (score 4) in PtC patients (Supplementary
Table 1). There were no differences in age or gender between
C-F and PtC patients (Supplementary Table 1). In addition,
40% of PtC patients and 50% of C-F patients were treated with
systemic cancer therapy administered either before (14/16) or
both before and during (2/16; both C-F) ipilimumab treatment
course (Supplementary Table 1).
Composition of the intestinal microbiota before colitis. To
characterize the intestinal microbial composition before immune-
mediated colitis, faecal samples were submitted for bacterial
microbiota proﬁling using 16S ribosomal RNA sequencing on the
Illumina MiSeq platform. C-F and PtC patients harboured
intestinal microbiota with similarly complex microbial popula-
tions and shared 239 of 578 operational taxonomic units (OTUs,
deﬁned at a 97% sequence similarity; Fig. 1b). These 239 shared
OTUs represent 79% and 83% of the total OTU abundance in the
C-F and PtC patient groups, respectively (Fig. 1c,d), and many
were present in 5 or more patients (Fig. 1e). In contrast, OTUs
that were either associated with only C-F or only PtC patients
were generally detected in fewer than ﬁve patients (Fig. 1e). The
OTUs that are shared between the two patient groups are more
evenly distributed. Roughly 20% of shared OTUs are found in
over half of all patients (Fig. 1e). These differences in the dis-
tribution of OTUs among the patient groups did not have a
signiﬁcant impact on the overall biodiversity (Supplementary
Fig. 1a,b). Microbial richness, reﬂecting the number of unique
phylotypes within a given sample, was found to be similar
between patients who developed CTLA-4 blockade-induced
colitis and those who remained C-F (Supplementary Fig. 1c,d).
To examine the intestinal microbiota structure between patient
groups, we plotted the relative frequencies of bacterial phylotypes
at the taxonomic level of family for each patient. Although C-F
and PtC patients shared many bacterial taxa that belong to the
Firmicutes phylum, C-F patients harbour a greater proportion
of microbes within the Bacteroidaceae family (Fig. 2a). Our
taxonomic classiﬁcations based on 16S sequencing data were
similar to those found when applying MetaPhlAn to shotgun
metagenomic sequencing data on a subset of this patient cohort,
although the proportions of some bacterial phyla vary between
the two methods (Supplementary Fig. 2). To illustrate the
microbiota composition with ﬁner resolution, we plotted the
relative abundances of 146 OTUs at 0.1% or greater mean
abundance. Although broad swaths of the microbiota are found at
similar frequencies between patients, microbes within the
Bacteroidetes phylum are underrepresented in the patients who
developed new-onset, immune-mediated colitis (Fig. 2b).
Members of Bacteroidetes phylum associated with resistance.
To further explore the relationship between speciﬁc bacterial
members of the intestinal microbiota and development of
CTLA-4 blockade-induced colitis, we stratiﬁed patients by their
severity of inﬂammation and performed a Spearman’s rank
correlation test on the relative abundances of bacterial species
grouped at different taxonomic levels. This analysis revealed
that taxa within the Bacteroidetes phylum are more prevalent
in C-F patient samples (Fig. 3a). The relative abundance of
OTUs classiﬁed as Bacteroidetes, as well as the number of
OTUs assigned to the phylum, were signiﬁcantly higher in C-F
patients (Mann–Whitney test, Po0.05; Fig. 3b,c). Within the
Bacteroidetes phylum, the prevalence of Bacteroidaceae,
Rikenellaceae and Barnesiellaceae is signiﬁcantly more
abundant in patients resistant to ipilimumab-induced colitis
(Mann–Whitney test, Po0.01, Po0.05 and Po0.05, respectively;
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Fig. 3d–f). Although the composition of the intestinal microbiota
can vary over the lifetime of an individual, there was no
association between patients’ age and the abundance of
Bacteroidetes (Supplementary Fig. 3).
Speciﬁc microbial modules associated with protection.
To evaluate the genetic pathways that may play a role in the
development of immune-mediated colitis, we performed shotgun
metagenomic sequencing on the 10 PtC and 12 C-F patient faecal
samples. Sequencing reads were processed using HUMAnN and
assigned to KEGG (Kyoto Encyclopedia of Genes and Genomes)
modules. The microbial modules that comprised patients’
intestinal microbiota were broadly similar between C-F and PtC
patients (Fig. 4a). We conducted a univariate test for associations
between colitis status and the 102 microbial modules using linear
discriminant analysis effect size (LEfSe) analysis. We found that
the spermidine/putrescine polyamine transport system and three
modules involved in the biosynthesis of B vitamins (riboﬂavin
(B2), pantothenate (B5) and thiamine (B1)) were more abundant
in C-F patients (Fig. 4b). After stratifying samples by colitis
status, a Spearman analysis identiﬁed the polyamine transport
system and thiamine (B1) modules as correlated with resistance
to the development of colitis (Fig. 4c). The relative abundances of
the aforementioned pathways are signiﬁcantly enriched in C-F
patient samples (Mann–Whitney test, Po0.05 for all modules;
Fig. 4d). In addition, a module involved in the biosynthesis of the
biotin (vitamin B7) was found in greater abundance in C-F
patients (Mann–Whitney test, Po0.05).
Select bacterial modules can identify colitis patients. We next
sought to assess the predictive accuracy of these microbial
modules in determining a patient’s risk for colitis. Using the
recursive partitioning machine learning algorithm to form a
classiﬁcation tree based on the 102 modules, samples were
successfully classiﬁed as from either PtC or C-F patients using the
relative abundance of polyamine transport system module alone
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Figure 1 | C-F and PtC patients harbour distinct microbial populations. (a) Faecal sample collection (blue circle) and the onset of colitis (red triangle)
are shown at the indicated time points during treatment with ipilimumab, a monoclonal antibody that blocks CTLA-4 signalling. Dates are relative to ﬁrst
dose of treatment. An average abundance40.01% was used as the threshold for considering an OTU to be present within faecal samples in either patient
group (OTUs, n¼ 578); OTUs at an abundance of r0.01% were not considered to be present in the patients’ microbiota. Using this deﬁnition,
we calculated (b) the number of OTUs present in C-F patients only (purple), PtC patients only (turquoise) or shared between the patient groups (blue) in a
scaled Venn diagram. (c) The mean relative abundance of OTUs, (d) total abundance of OTUs, (e) distribution of OTUs that are present in C-F patients
only, PtC patients only or shared between the patient. C-F patients, n¼ 24; PtC patients, n¼ 10. OTUs, operational taxonomic units.
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(Fig. 5a). Samples with41% relative abundance of the polyamine
transport system were binned as C-F (Supplementary Fig. 4). Of
the PtC patients, 7 samples were appropriately identiﬁed, whereas
3 samples were misclassiﬁed as C-F, resulting in a sensitivity of
70% and speciﬁcity of 100% (Fig. 5a). Performing a leave-one-out
cross-validation of the probit regression analysis based on 4 of the
modules associated with C-F patients, we correctly predicted the
colitis status for 10 out of 12 C-F patients and 7 out of 10 PtC
patients, at a probability threshold of 50% (Fig. 5b). This model
results in a sensitivity of 70% and speciﬁcity of 83%. For this
regression analysis, we selected the four modules associated with
resistance to colitis that were identiﬁed in the Spearman and
LEfSe analyses, which include the polyamine transport system
module and modules involved in the biosynthesis of vitamins
riboﬂavin (B2), pantothenate (B5) and thiamine (B1). These
modules performed better in combination than any individual
module (Fig. 5c). Taken together, our four-module analysis
predicts colitis risk with good accuracy as demonstrated by
receiver operating characteristic curve, for which there are no
other known biomarkers presented in the literature to use for
comparison (Fig. 5d)12,15. In all, these analytical models identify
bacterial pathways that may confer resistance to colitis and serve
as biomarkers for patients at high risk of developing CTLA-4
blockade-induced colitis.
Discussion
Our study is the ﬁrst to characterize the intestinal microbiota of
patients before the development of intestinal inﬂammation and
has identiﬁed microbiota-associated biomarkers that correlate
with protection against CTLA-4 blockade-associated colitis.
Our ﬁnding that members of the Bacteroidetes phylum
are enriched in colitis-resistant patients is consistent with a
proposed immunomodulatory role of these commensal bacteria.
Bacteroidetes represents one of the major phyla of the human
colonic microbiota and its members can limit inﬂammation by
stimulating T-regulatory cell differentiation16,17. In addition, we
show that the presence of microbiota-associated modules for
bacterial polyamine transport system and the biosynthesis of
thiamine, riboﬂavin and pantothenate can accurately assess a
patient’s risk of developing colitis following CTLA-4 blockade.
The microbiota plays an important role in the endogenous
synthesis of water-soluble B vitamins18–20. Thiamine and
riboﬂavin concentrations are signiﬁcantly reduced in the blood
of patients with Crohn’s disease and the levels of bound
pantothenate in the colonic mucosa decrease with the
progression of inﬂammatory bowel disease21,22. An innate-like
T-cell population known as mucosal-associated invariant T cells
are activated in vitro by riboﬂavin metabolites23. These cells
accumulate in the inﬂamed mucosa of Crohn’s disease patients,
although it is not yet known whether their interleukin-17-skewed
cytokine expression exacerbates or limits inﬂammation24.
Polyamines, which are small cationic amines that can be
exported from bacteria cells through the spermidine and
putrescine transport system (potA, B, C and D), play an
anti-inﬂammatory role by promoting colonic epithelial cell
proliferation to maintain the epithelial barrier25. In patients
with active colitis, levels of orthinine decarboxylase, the enzyme
involved in polyamine synthesis, are lower than in control
patients, but it remains unclear whether reduced polyamine levels
contribute to colitis development or progression26,27. Additional
studies are required to further explore whether a reduced capacity
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for microbe-mediated production of B vitamins and polyamine
transport lowers the threshold for initiation of immune-mediated
colitis.
Other checkpoint-blockade therapies, such as anti-PD1, can
lead to adverse gastrointestinal events28. In the case of anti-PD-L1
and anti-CTLA-4 blockade, as well as CpG-oligonucleotide
immunotherapy and cyclophosphamide, therapeutic response is
affected by the intestinal microbiota29–32. As with treatment
efﬁcacy, the microbiota may play a role in the development of
immune-mediated, new-onset colitis in the context of other
immunotherapies. Identiﬁcation of biomarkers that predict the
risk of developing colitis may help identify patients that are
particularly susceptible to distinct forms of immunotherapy-
induced inﬂammation, such as with CTLA-4 blockade, and may
facilitate preemptive treatments.
Methods
Study patients and specimen collection. Thirty-four adults analysed in our study
were diagnosed with metastatic melanoma and received ipilimumab at Memorial
Sloan-Kettering Cancer Center. Subjects had no previous history of colitis and
bowel resection, and had not received antibiotic treatment in the preceding 2
months. Patients were excluded from analysis if the ﬁrst faecal sample was collected
after the onset of colitis, if the patient did not receive ipilimumab, or if colitis status
was unknown. Ipilimumab monotherapy was administered at a dose of 3mg kg 1
every 3 weeks for up to four doses, with three exceptions. Patients #10 and #15
received vemurafenib before and during ipilimumab treatment as part of a clinical
trial. Patient #13 was part of a blinded clinical trial and received ipilimumab at
either 3 or 10mg kg 1. A small number of patients (PtC, n¼ 2; C-F, n¼ 3)
received additional doses of ipilimumab either as part of maintenance treatment
(every 3 months) on a clinical study or as part of a second course of ipilimumab;
however, the colitis cases documented here occurred before this additional dosing
was administered. Systemic cancer treatment administered before (n¼ 14) or both
before and during (n¼ 2) ipilimumab therapy was determined retrospectively on
chart review by a single investigator (MKC). For 30 patients, faecal samples were
collected from each participant before the ﬁrst administration of ipilimumab; for
2 patients who developed gastrointestinal inﬂammation and 2 patients who
remained inﬂammation free, samples were collected after the initiation of CTLA-4
blockade, but before onset of colitis. Toxicities were graded retrospectively by a
single investigator (MKC) based on chart review using CTCAE, version 4.0, and
grading on the terms diarrhoea and colitis. Patients were assigned a colitis score
based on the following: no diarrhoea (score 0), grade 1 diarrhoea (score 1), grade 2
diarrhoea (score 2), grade 2 diarrhoea and/or grade 2 colitis (all 3 cases had both
grade 2 diarrhoea and grade 2 colitis) (score 3), grade 3 diarrhoea and/or grade 3
colitis (1 case with both grade 3 diarrhoea and grade 3 colitis) (score 4). All
participants provided written consent for specimen collection and analysis under
the study protocol approved by the Memorial Sloan-Kettering Cancer Center
Institutional Review Board.
DNA extraction. Each faecal sample was immediately snap-frozen at  80 C and
subsequently subjected to bead beating and phenol chloroform extraction for DNA
puriﬁcation. Samples were resuspended in 500 ml of an extraction buffer (200mM
Tris pH 8.0/200mM NaCl/20mM EDTA), 200 ml of 20% SDS, 500 ml of phenol:-
chloroform:isoamyl alcohol (24:24:1) and 500 ml of 0.1-mm diameter zirconia/silica
beads (BioSpec Products). For 2min, cells were lysed by mechanical disruption
using a bead beater. DNA was extracted in a phenol/chloroform/isoamyl solution
twice and precipitated with ethanol and sodium acetate. DNA was resuspended in
200 ml of TE buffer containing 100 mgml 1 RNase and further puriﬁed using
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QIAmp Mini Spin Columns (Qiagen). After eluting the sample in 100 ml of distilled
water, double-stranded DNA was quantiﬁed.
16S rRNA gene ampliﬁcation and multiparallel sequencing. The V4–V5 region
of the 16S rRNA gene was ampliﬁed and sequenced on an Illumina MiSeq
platform. For each faecal sample, replicate PCR reactions were performed using
modiﬁed universal bacterial primers designed to amplify the V4-V5 16S rRNA
region: 563F (59-nnnnnnnn-NNNNNNNNNNNN-AYTGGGYDTAAAGN G-39)
and 926R (59-nnnnnnnn-NNNNNNNNNNNN-CCGTCAATTYHTTTR
AGT-39). Each reaction contained 50 ng of puriﬁed DNA, 0.2mM dNTPs, 1.5 mM
MgCl2, 1.25U Platinum TaqDNA poly-merase, 2.5 ml of 10 PCR buffer and
0.2 mM of each primer. A unique 12-base Golay barcode (Ns) preceded the primers
for sample identiﬁcation after pooling amplicons. One to eight additional
nucleotides were added before the barcode to offset the sequencing of the primers.
Cycling conditions were the following: 94 C for 3min, followed by 27 cycles of
94 C for 50 s, 51 C for 30 s and 72 C for 1min, where the ﬁnal elongation step
was performed at 72 C for 5min. Replicate PCRs were combined and were
subsequently puriﬁed using the Qiaquick PCR Puriﬁcation Kit (Qiagen) and
Qiagen MinElute PCR Puriﬁcation Kit. Using the Illumina TruSeq Sample
Preparation procedure, PCR products were quantiﬁed and pooled at equimolar
amounts before Illumina barcodes and adaptors were ligated on. The completed
library was sequenced on an Ilumina Miseq platform according to the Illumina
recommended protocol.
Sequence analysis. Sequences were analysed using mothur version 1.31.1
(ref. 33). Sequences were aligned using the Silva reference alignment as a template
and potentially chimeric sequences were eliminated using the UChime algorithm34.
Five thousand sequences per patient were selected (mean 4,974, s.d. 150) and
sequences with a distance-based similarity of Z97% were grouped into OTUs
using the furthest-neighbour algorithm. OTUs were classiﬁed using the Greengenes
16S rRNA reference database. OTU-based microbial diversity was estimated by
calculating two diversity indices, Shannon and Inverse Simpson. OTU-based
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richness was determined by calculating the Chao richness estimate and
constructing rarefaction curves. OTUs were grouped at different levels of
classiﬁcation (phylum, class, order, family and genus); at each level, OTUs that did
not have a classiﬁcation were grouped together by the highest available resolution
(for example, at the genus level, an OTU classiﬁed as p__Bacteroidetes_c__
Bacteroidia_o__Bacteroidales_ f__Barnesiellaceae_unclassifed would be grouped as
f__Barnesiellaceae_unclassifed). Feature selection of the intestinal microbia’s
composition was performed on OTUs with an average abundance 40.01% in
either patient group and grouped by phylotype.
Shotgun sequencing and metabolic pathway reconstruction. Stool samples
from all 10 PtC patients and 12 C-F patients were subjected to shotgun sequencing.
C-F patient samples were chosen so that the full spectrum of Bacteroidetes phylum
abundance was represented. Libraries were constructed with Illumina barcodes
from the TruSeq DNA Sample Prep kit (Illumina) and reagents from KAPA
Library Preparation kit (Kapa Biosystems), and then sequenced on an Illumina
MiSeq platform using 2 250 nucleotide paired-end sequencing, according to the
manufacturer’s instructions. Sequencing reads were converted into relative
abundances of microbial metabolic modules using HUMAnN35, the Human
Microbiome Project metabolic reconstruction pipeline and mapped to the KEGG36.
Relative species abundances were calculated by the MetaPhlAn pipeline37.
Statistics. Statistical analyses of intestinal microbiota samples were performed
using R Statistical Language (v3.1.1) and GraphPad Prism (version 6.0e) software
packages. Unpaired Mann–Whitney rank sum test (two-tailed) was used for
comparisons of continuous variables between two groups. Bar plots were used to
represent the data’s mean at the centre values, with error bars to indicate s.d.
Spearman’s rank correlation tests (two-tailed) were used to ﬁnd signiﬁcant
correlations between two continuous variables. LEfSe was used to identify
differentially abundant features between classes of samples38. Recursive
partitioning to form classiﬁcation trees was performed in R using the package rpart.
Generalized linear model (using probit regression and the glm R-function)
was constructed on all combinations of the following ﬁve modules associated
with C-F patients: polyamine transport system (M299), riboﬂavin biosynthesis
(M125), pantothenate biosynthesis (M119), thiamine biosynthesis (M127) and
biotin biosynthesis (M123). Leave-one-out cross-validation was used to compute
model sensitivity and speciﬁcity. The reported model provided the best total
sensitivity plus speciﬁcity. Unadjusted P-values o0.05 were considered to
be signiﬁcant for the Mann–Whitney rank sum test and Spearman’s rank
correlation tests.
Code availability. Code, written in R version 3.2.2, and instructions are provided
in the Supplementary Software ﬁle.
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